[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burns\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burns":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,40,77,103,134,158,187,212,242,267,286,307,333,361,384,406,433,452,471,496,517,548,569,595,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100645134","deepview-hhf-training-and-validation-study-100645134",false,"NCT07677657","Deepview HHF Training and Validation Study","Deepview HHF Training and Validation Label Expansion Study","UK HHF","Inclusion Criteria:\n\n1. Willing and able to give informed consent, have a witnessed verbal consent, family discussion if intubated and retrospective consent for those that are intubated\n2. Life expectancy \\> 1 month\n3. Thermal burn mechanism (flame, scald, or contact)\n4. The Study Burn(s) occurred less than 72 hours prior to the time of first imaging\n5. Minimum burn wound size for adult or paediatric participants is 0.25% TBSA per region\n6. Have burn(s) on the head, hands and\u002For feet that meet the criteria for a Study Burn. If multiple regions meet the Study Burn criteria, per the discretion of the Investigator, all Study Burn regions should be included.\n\nExclusion Criteria:\n\n1. Sepsis at the time of enrolment\n2. Infection of the burn wound at the time of enrolment\n3. Immunosuppression \u002F radiation \u002F chemotherapy \\\u003C 3 months prior to enrolment\n4. Concurrent use of investigational products with a known effect on the burn sites; and\u002For imaging\n5. Concurrent use of products such as chemical debriding agents, skin substitutes and others that the principal investigator deems will have an impact on the image quality and healing potential of a Study Burn\n6. Any condition that, in the opinion of the Investigator, may prevent compliance with the study requirements or compromise Participant safety\n7. Participants without a burn on the hands, feet, head or neck, or burns located on these regions only on the palmar or plantar surfaces\n8. Chemical or any other non-thermal burns\n\n8\\. Participants anticipated to or undergoing enzymatic debridemen9","ALL",{"count":20,"type":21},280,"ESTIMATED","OBSERVATIONAL","The purpose of this Study is to help expand the use of the DeepView AI System so that it can assess burn injuries on the hands, head\u002Fface, and feet. To do this, the Study will collect new images of burns in these areas. Some of these images will be used to improve and retrain the AI system, while others will be used to test how well the updated system performs. The images for both purposes will be collected at the same time. The new images from the hands, head\u002Fface, and feet will then be combined with existing images from other body areas. This will allow researchers to determine whether the updated AI system performs as well as, or better than, previous versions of the technology. For participants with Study Burns requiring surgical excision, the Study site clinician will collect punch biopsies from the Study Burn according to a standardised burn wound punch biopsy collection.",[25,26,27],"Burns","Burn Injury","Diagnostic","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2027-05-01",{"name":38,"class":39},"SpectralMD","INDUSTRY",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100644664","foreign-national-burn-patients-in-a-border-region-burn-center-100644664","NCT07673796","Foreign-National Burn Patients in a Border-Region Burn Center","Clinical Characteristics and In-Hospital Outcomes of Foreign-National Burn Patients in a Border-Region Burn Center: A Retrospective Cohort Study","Inclusion Criteria: Patients hospitalized and treated with a diagnosis of burn injury at the Burn Center of Gaziantep City Hospital between October 2023 and June 2026.\n\nPatients with a confirmed diagnosis of burn injury in patient files, discharge summaries, or hospital information management system records.\n\nPatients whose nationality status can be classified as Turkish citizen or foreign-national according to hospital records.\n\nPatients with available basic demographic, clinical, and in-hospital outcome data.\n\nPatients of all age groups and both sexes.\n\nExclusion Criteria: Patients treated outside the predefined study period. Patients without a confirmed diagnosis of burn injury. Patients evaluated only in the outpatient setting without hospitalization. Patients with missing nationality data. Patients with insufficient demographic or clinical outcome data for analysis. Duplicate records related to the same burn event; only the first hospitalization will be included.\n\nPatients evaluated only for consultation without hospitalization at the Burn Center of Gaziantep City Hospital.\n\n\\-",{"count":48,"type":21},1400,"This retrospective cohort study will evaluate burn patients hospitalized and treated at the Burn Center of Gaziantep City Hospital between October 2023 and June 2026. The study aims to compare demographic characteristics, burn severity, clinical course, and in-hospital outcomes between Turkish citizens and foreign-national burn patients.\n\nData will be obtained retrospectively from patient files, discharge summaries, intensive care records, operative notes, and the hospital information management system. Variables will include age, sex, nationality status, burn etiology, total body surface area burned, inhalation injury, sepsis, intensive care unit admission, mechanical ventilation requirement, surgical treatment requirement, number of operations, length of hospital stay, discharge status, transfer to another center, and in-hospital mortality.\n\nNo additional intervention, diagnostic test, treatment, or follow-up procedure will be performed as part of this study. All analyses will be conducted using anonymized or coded retrospective clinical data.",[26,25],[52,53,54,55,56,57,58,59,60,61,62,63,64,65,66],"Burn injury","Burn center","Foreign-national patients","Refugees","Border region","Retrospective cohort","Total body surface area","Inhalation injury","Intensive care","Mechanical ventilation","Sepsis","In-hospital mortality","ABSI score","Revised Baux score","Ryan-based modified clinical score","2026-06-23",{"date":69,"type":32},"2026-06-29",{"date":71,"type":21},"2026-07",{"date":73,"type":21},"2026-09",{"name":75,"class":76},"Gaziantep City Hospital","OTHER",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100553578","differential-pressure-distribution-orthosis-by-3d-printing-process-in-the-treatment-of-post-burn-hypertrophic-scarring-100553578","NCT06487910","Differential Pressure Distribution Orthosis by 3D Printing Process in the Treatment of Post-burn Hypertrophic Scarring","Pilot Study on the Design of a 3D-printed Differential Pressure Distribution Orthosis for the Treatment of Post-burn Hypertrophic Scarring","EPIDERM","Inclusion Criteria:\n\n* Adult Patients aged \\> 18 years old\n* Patient with at least one hypertrophic burn scar in the process of healing localized on a skin area that can benefit from a compression garment and requiring the use of an ORDP\n* Patient able to give informed consent\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship or safeguard of justice\n* Pregnant or breast-feeding women","18 Years",{"count":7,"type":21},"INTERVENTIONAL",[89],"NA","This is a pilot, single-center, feasibility study to evaluate a new 3D printing method for ORDP design.\n\nTo our knowledge, there is no technical or clinical evaluation of ORDPs, particularly in the treatment of hypertrophic scars. The aim of our study is therefore to assess the feasibility of an innovative method of designing ORDPs for the curative treatment of post-burn hypertrophic scars, using a 3D printing process, and to describe the procedures (production time and cost).",[25,92],"Hypertrophic Scar","RECRUITING","2026-06-20",{"date":29,"type":32},{"date":97,"type":32},"2025-01-10",{"date":99,"type":21},"2027-01-10",{"name":101,"class":76},"Centre Hospitalier Régional Metz-Thionville",1,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":87,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":102},"100641098","early-intervention-to-prevent-development-of-ptsd-in-burn-survivors-and-their-caregivers-100641098","NCT07656545","Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers","Inclusion Criteria:\n\n* Alert, oriented, \\& not withdrawing from substance at time of screening\n* Can read and write in English\n* Hospitalized within 10 days of burn injury\n* Anticipated discharge \\\u003C=4 weeks\n* Have an email, mailing address, and at least 1 smart device for telehealth sessions\n* PTSD risk score of 2 or greater (patient-only)\n* Willing to attend therapy sessions with a loved one\n\nExclusion Criteria:\n\n* Currently incarcerated or in police custody\n* \\> 10 days post-burn\n* Lifetime diagnosis of primary psychosis or intellectual disability\n* Ongoing reported domestic violence in the dyad\n* Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury\n* Inflammation Confounds (patient-only) of BMI \\> 40, metabolic syndrome, admission A1C of \\>= 6.5%\n* Currently receiving couples therapy",true,{"count":111,"type":21},44,[89],"The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers. This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization. The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma. The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching. The clinical trial will occur in two sequential phases. In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention. All four adults will receive the intervention. In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC). The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.",[115,25,116,117,118,119,120,121,122,123,124],"Posttraumatic Stress Disorder","Traumatic Injury","Acute Stress Disorder","Trauma and Stressor Related Disorders","Trauma and Stress Related Disorders","Stress Disorder","Stress Disorders, Post-Traumatic","Stress Disorders, Traumatic","Stress Disorders, Traumatic, Acute","Relationship, Social","2026-06-14",{"date":127,"type":32},"2026-06-18",{"date":129,"type":21},"2026-08-01",{"date":131,"type":21},"2029-02-28",{"name":133,"class":76},"University of Southern California",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":109,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":102},"100639478","theravex-tissue-care-spray-plus-for-the-management-of-cutaneous-wounds-burns-and-chronic-ulcers-100639478","NCT07617961","THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers","Pilot Clinical Evaluation of THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers","Inclusion Criteria\n\nAdult patients aged 18 years or older. Patients presenting with cutaneous wounds: burns, traumatic wounds, pressure ulcers, diabetic ulcers, or chronic cutaneous lesions.\n\nPatients considered clinically suitable for topical treatment with THERAVEX Tissue Care Spray Plus.\n\nExclusion Criteria Known allergy or hypersensitivity to any component of THERAVEX Tissue Care Spray Plus.\n\nPresence of severe uncontrolled systemic infection requiring immediate surgical intervention.\n\nParticipation in another interventional clinical study that could interfere with wound healing assessment.",{"count":142,"type":21},26,"Pilot observational clinical evaluation assessing the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy for the management of cutaneous wounds, burns, traumatic lesions, pressure ulcers, diabetic ulcers, and chronic ulcers in 26 patients. The study evaluated wound healing progression, epithelialization, tissue hydration, inflammatory response, tolerance, and overall clinical evolution in patients receiving standard wound care combined with topical application of THERAVEX Tissue Care Spray Plus. Preliminary observations demonstrated favorable tissue response, progressive epithelial regeneration, reduction of inflammatory signs, and absence of treatment-related adverse events.",[145,25,146,147,148],"Chronic Wounds","Pressure Ulcer","Traumatic Wounds","Diabetic Foot Ulcer","2026-06-01",{"date":151,"type":32},"2026-06-04",{"date":153,"type":32},"2025-10-02",{"date":155,"type":21},"2027-05-21",{"name":157,"class":39},"Biointelligent Technology Systems SL",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":87,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100636496","frenkel-exercises-on-balance-and-quality-of-life-post-burns-100636496","NCT07566442","Frenkel Exercises on Balance and Quality of Life Post Burns","Effect of Frenkel Exercises on Balance and Quality of Life in Patients With Lower Limb Burns","Inclusion Criteria\n\n* Body mass index (BMI) between 25-30 kg\u002Fm²\n* Total body surface area (TBSA) 30%-45% determined by rule of nines\n* Second-degree thermal burns affecting the lower limbs\n* After full wound healing\n* Ability to stand and walk independently or with minimal assistance\n* Ability to participate in balance training exercises\n\nExclusion Criteria\n\n* Open wounds in or near the treatment area\n* Chemical or electrical burns or inhalation injuries\n* Musculoskeletal conditions affecting exercise or testing, or visual\u002Fhearing impairments\n* Uncontrolled cardiovascular or pulmonary diseases\n* Malignant conditions\n* Severe behavioral or cognitive disorders\n* Uncooperative patients\n* Proprioception deficit or balance impairment due to other diseases","20 Years","45 Years",{"count":168,"type":21},70,[89],"Seventy patients of both sexes with thermal burn injuries, aged 25 to 45 years, will participate in this study. The participants will be randomly selected from the Outpatient Clinic of the Faculty of Physical Therapy. They will be randomly assigned into two equal groups, 35 patients each (study group and control group). Group A (Study Group): Patients in this group will receive Frenkel exercises in addition to a traditional physiotherapy program comprising stretching, strengthening exercises and scar management, 3 times a week for 8 weeks. While, Group B (Control Group): Patients in this group will receive traditional physiotherapy program, 3 times a week for 8 weeks.",[25,172],"Lower Limb Burn Injury",[174,175,176,177,178],"Balance","Frenkel exercises","Quality of life","Burn","Functional mobility","2026-05-31",{"date":181,"type":32},"2026-06-02",{"date":179,"type":21},{"date":184,"type":21},"2026-09-12",{"name":186,"class":76},"Cairo University",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":165,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":102},"100639886","validity-and-reliability-of-arabic-version-of-michigan-hand-questionnaire-in-assessment-of-hand-function-post-burn-100639886","NCT07614971","Validity and Reliability of Arabic Version of Michigan Hand Questionnaire in Assessment of Hand Function Post-burn","Validity and Reliability of Arabic Version of Michigan Hand Outcomes Questionnaire in Assessment of Hand Function Post-burn","Inclusion Criteria:\n\n* Both genders are participated in this study.\n* All patients suffering from second degree thermal burn injury involving the dorsal surface of the dominant hand with TBSA ranged from 20% to30%.\n* All patients will be asked to fill the questionnaire after 1 month from burn injury and they will be asked to refill the questionnaire after 1 week.\n* All participants can read and write in Arabic.\n* All participants can understand items of the questionnaire easily.\n* All patients enrolled to the study had their informed consent\n\nExclusion Criteria:\n\n* Patients with cognitive and psychiatric disorders.\n* Patients with palmar and circumferential hand burn.\n* Patients with communication, vision and hearing disorders.\n* Patient who don't fill the questionnaire till the end.\n* Patient who aren't cooperative in filling the questionnaire.\n* Suicidal burn.","35 Years",{"count":196,"type":21},100,"The purpose of the study will to test the:\n\n* Face validity of Arabic version of Michigan Hand Outcomes Questionnaire in assessment of hand function post burn.\n* Content validity of Arabic version of Michigan Hand Outcomes Questionnaire in assessment of hand function post burn.\n* Concurrent validity of Arabic version of Michigan Hand Outcomes Questionnaire in assessment of hand function post burn.\n* Feasibility of Arabic version of Michigan Hand Outcomes Questionnaire in assessment of hand function post burn.\n* Internal consistency reliability of Arabic version of Michigan Hand Outcomes Questionnaire in assessment of hand function post burn.\n* Test- retest reliability of Arabic version of Michigan Hand Outcomes Questionnaire in assessment of hand function post burn.",[25],[177,200,201,202,203],"Hand function","Michigan Hand Outcomes Questionnaire","Validity","Reliability","2026-05-22",{"date":206,"type":32},"2026-05-29",{"date":208,"type":21},"2026-05",{"date":210,"type":21},"2026-12",{"name":186,"class":76},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":87,"phases":221,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":102},"100630984","early-phase-1-topical-methylene-blue-photodynamic-therapy-mb-pdt-for-burn-wound-infection-100630984","NCT07494773","Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection","Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection: A Prospective Randomized Pilot Study","Inclusion\n\n* Age ≥18\n* Partial- or full-thickness burn with partial-thickness component\n* Expected ≥7 days dressing changes\n* Able to consent\n\nExclusion\n\n* Pregnancy or lactation\n\n  o Pregnancy status will be determined by review of the medical record and, when clinically indicated per institutional policy, standard-of-care pregnancy testing. No additional pregnancy testing will be performed solely for research purposes.\n* Current use of SSRIs, SNRIs, MAO inhibitors, and other serotonergic agents\n* Inability to tolerate wound exposure\n* Inability to consent\n* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency",{"count":220,"type":21},50,[222],"EARLY_PHASE1","Burn wound infections remain a major source of morbidity in patients with thermal injuries and contribute to delayed healing, graft loss, and prolonged hospitalization. The emergence of antimicrobial-resistant organisms further complicates management and highlights the need for non-antibiotic antimicrobial strategies. Photodynamic therapy (PDT) is an antimicrobial approach that combines a photosensitizing agent with visible light to generate reactive oxygen species capable of killing bacteria.\n\nThis randomized clinical trial will evaluate the safety and preliminary efficacy of methylene blue-mediated photodynamic therapy for the treatment of burn wound bacterial contamination. Participants receiving standard burn care will be randomized to receive either methylene blue-photodynamic therapy with blue light illumination or light therapy alone during routine dressing changes. Treatments will occur during two consecutive dressing changes. The primary objective is to determine whether methylene blue photodynamic therapy reduces bacterial burden in burn wounds compared with light therapy alone. Secondary outcomes include safety, tolerability, and effects on wound healing.",[25,225],"Wound Infection",[227,228,229,230,231,232],"Photodynamic Therapy","Methylene Blue","Burn Wound Infection","Antimicrobial Photodynamic Therapy","Reactive Oxygen Species","Burn Wound Bacterial Burden","2026-05-14",{"date":235,"type":32},"2026-05-19",{"date":237,"type":21},"2026-06",{"date":239,"type":21},"2028-05-31",{"name":241,"class":76},"University of Oklahoma",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":87,"phases":250,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":102},"100439337","phase-1-a-between-patient-study-of-plurogel-compared-to-standard-topical-dressing-in-burn-injuries-100439337","NCT05000983","A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","A Between Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","Inclusion Criteria:\n\n* Persons with partial thickness face burns or unilateral limb burn injuries requiring admission.\n\nExclusion Criteria:\n\n* Total burn surface area (TBSA) \\>30%.\n* Burn depth full thickness or deeper on initial assessment.\n* Prior excision at another healthcare centre.\n* Patients with pre-existing malnutrition\n* Electrical, chemical or other unusual burn etiologies",{"count":7,"type":21},[251,252],"PHASE1","PHASE2","Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full thickness areas. Demarcation can be appreciated on admission for full thickness burns but is often a prolonged process that can last weeks. The clinical evaluation of the depth of the burn is a complex decision that often is made more challenging by the presence of the proteinaceous pseudoeschar and the coagulated dermis itself. Surgical debridement is relatively 'coarse' and by its very nature requires removal of a thin layer of viable tissue to reach the level that is vascularized enough to support a skin graft. There has been growing interest in the use of adjuncts to reduce the amount tissue debrided and potentially reduce the need for surgery itself. Operatively, there have been some reports that use of hydro-dissection devices (Versajet™) may allow a more controlled debridement, resulting in less viable tissue being sacrificed. There is also a growing experience with enzymatic debridement, especially with Bromolein, derived from Pineapple (NexoBrid®). Neither of these have been shown to definitively improve care in randomized controlled trials, (RCTs) and there is suggestion that in some settings may actually cause harm.",[25],[256,257,258],"burn","wound","debridement","2026-05-11",{"date":233,"type":32},{"date":262,"type":32},"2021-10-20",{"date":264,"type":21},"2029-12-31",{"name":266,"class":76},"University of Manitoba",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":87,"phases":276,"briefSummary":253,"conditions":277,"keywords":278,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":102},"100431113","phase-1-a-study-of-plurogel-compared-to-standard-topical-dressing-in-burn-injuries-100431113","NCT04893863","A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","A Within Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","Inclusion Criteria:\n\n* Persons with bilateral limb partial thickness burn injuries of similar depth requiring admission\n\nExclusion Criteria:\n\n* Total body surface area (TBSA) of burn \\>30%.\n* Burn depth full thickness or deeper on initial assessment.\n* Prior excision at another healthcare centre.\n* Patients with pre-existing malnutrition\n* Electrical, chemical or other unusual burn etiologies",{"count":275,"type":21},20,[251,252],[25],[256,257,279,258],"dressing",{"date":233,"type":32},{"date":282,"type":32},"2021-10-01",{"date":284,"type":21},"2029-06-01",{"name":266,"class":76},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":87,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":102},"100339160","early-phase-1-a-pilot-trial-of-disposable-nitrous-oxide-canisters-in-providing-pain-control-during-burn-dressing-changes-100339160","NCT03695887","A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes","A Pilot Randomized Controlled Crossover Trial of the Effectiveness of Disposable Nitrous Oxide Canisters in Providing Improved Pain Control During Burn Dressing Changes.","Inclusion criteria\n\n* adult burn patients admitted to the Health Sciences Centre\n* total body surface area burned of 5-20%\n\nExclusion criteria\n\n* admitted to intensive care unit\n* unable to participate in the measurement outcomes (sedated, cognitively impaired, unable to understand English or visually impaired)\n* medical condition that precludes using nitrous oxide (respiratory disease and significant cardiovascular disease 5).\n* pregnant\n* physically unable to hold the canister\n* \\\u003C90% SaO2 on room air\n* face burn\n* pre-injury narcotics (relative exclusion)\n* use of IV ketamine\n* pre-existing lung injury",{"count":294,"type":21},30,[222],"Improvements in burn care have resulted in increased survival. Despite these improved outcomes one of the leading challenges of burn care remains providing adequate analgesia during routine wound care and dressing changes. The traditional use of narcotics is challenging as the therapeutic window between analgesia and suppression of breathing becomes narrow with the intense pain and high doses of narcotics needed for dressing changes.",[25,298],"Pain, Acute",[300],"burns, pain, dressing change, nitrous oxide",{"date":233,"type":32},{"date":303,"type":32},"2019-10-01",{"date":305,"type":21},"2029-12-01",{"name":266,"class":76},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":87,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":102},"100636626","efferon-lps-hemoadsorption-in-in-patients-with-thermal-burns-100636626","NCT07568132","Efferon LPS Hemoadsorption in in Patients With Thermal Burns","Extracorporeal Blood Purification Using Efferon LPS Hemoadsorption in Patients With Thermal Burns: Pilot Study","Inclusion Criteria:\n\n* Thermal burns (flame, scald, or contact burns), including cases combined with inhalation injury\n* Revised Frank Index (RFI) score ≥71 and ≤181\n* Indication for extracorporeal therapy within the first 10 days after injury\n* The patient's condition allows Efferon LPS therapy to be performed for at least 6 hours\n\nExclusion Criteria:\n\n* Isolated thermal-inhalation injury\n* Chemical, electrical, or solar burns of the skin\n* Combined skin burns with frostbite and\u002For general hypothermia\n* Combined trauma (electrical injury; traumatic brain injury other than concussion or mild cerebral contusion; skull, spinal, thoracic, pelvic, or femoral fractures) or acute pre-existing pathology prior to hospital admission (acute myocardial infarction, stroke, community-acquired pneumonia, or acute surgical conditions) that may influence the course and outcome of burn disease\n* Cardiopulmonary resuscitation at the pre-hospital stage\n* End-stage renal disease\n* Acute pulmonary embolism confirmed by imaging\n* Emergency surgical treatment\n* Any other condition which, in the investigator's opinion, precludes inclusion of the patient in the study","65 Years",{"count":220,"type":21},[89],"The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression of multiple organ dysfunction or to arrest its development in patients with burn disease with an RFI score ≥71 and ≤181.\n\nPatients will be randomized in two groups: control group receiving baseline therapy (including CRRT) and treatment group receiving baseline therapy and Efferon® LPS hemoadsorption in combination with CRRT.",[25],[320,321,322,323],"Hemoadsorption","Hemoperfusion","Extracorporeal therapy","LPS adsorption","2026-04-28",{"date":326,"type":32},"2026-05-05",{"date":328,"type":21},"2026-05-15",{"date":330,"type":21},"2028-02-27",{"name":332,"class":39},"Efferon JSC",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":87,"phases":343,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100635806","nano-fat-grafting-for-post-burn-scars-on-the-chest-shoulders-and-back-100635806","NCT07557472","Nano-Fat Grafting for Post-Burn Scars on the Chest, Shoulders, and Back","Evaluation of Nano-Fat Grafting in Post-Burn Hypertrophic Scars at Chest, Shoulders, and Back","Inclusion Criteria:\n\n* Age 18 to 50 years.\n* Presence of post-burn hypertrophic scars located on the chest, shoulders, or back.\n* Age of the scar is less than 6 months.\n\nExclusion Criteria:\n\n* Active infection or ulceration at the site of the scar.\n* Patients with systemic connective tissue diseases or bleeding disorders.\n* Hypertrophic scars older than 6 months.\n* History of keloids or previous surgical excision of the same scar.\n* Previous corticosteroid injections into the scar.\n* Pregnancy and lactation.\n* Refusal to undergo surgery.","50 Years",{"count":342,"type":21},55,[89],"This study aims to evaluate the effectiveness of nano-fat grafting in treating hypertrophic scars caused by burns on the chest, shoulders, and back.\n\nBurn scars in these specific areas are often difficult to treat because the skin is under constant tension and motion, which can prolong inflammation and worsen the scar. While conventional scar treatments like silicone patches, pressure garments, and steroid injections are widely used, they do not always completely restore normal tissue. Nano-fat grafting is emerging as a promising regenerative option. This procedure involves taking a small amount of the patient's own fat and processing it into a liquid that is rich in healing cells. This liquid is then injected directly into the scar to potentially improve skin texture, color, and flexibility.\n\nThe study will enroll 55 participants between the ages of 18 and 50. To be eligible, patients must have a post-burn hypertrophic scar on their chest, shoulder, or back that is less than 6 months old.\n\nDuring the study, doctors will harvest a small amount of fat from the patient's abdomen or thighs using a small tube. This fat will be carefully washed, processed, and passed through a special filter to create liquid nano-fat. The liquid is then gently injected into the scar tissue.\n\nResearchers will monitor the patients and evaluate the scars at 1, 3, and 6 months after the injection. They will use standard clinical scar assessments (the Vancouver Scar Scale and the Patient and Observer Scar Assessment Scale) alongside photographs to measure improvements in scar color, thickness, pliability, and overall appearance, as well as patient-reported symptoms like pain and itching.",[346,347,25],"Hypertrophic Scars","Post-burn Scars",[349,350,351,352],"Nano-fat Grafting","Fat Grafting","Scar Rejuvenation","Autologous Fat Injection","2026-04-23",{"date":355,"type":32},"2026-04-29",{"date":237,"type":21},{"date":358,"type":21},"2027-07",{"name":360,"class":76},"Assiut University",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":87,"phases":369,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":383},"100155597","phase-2-phase-2-pilot-study-of-the-safety-and-efficacy-of-topical-mw-iii-in-thermal-burns-100155597","NCT01297400","Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns","Inclusion Criteria:\n\n1. Adults, 18 years of age or older on the day of signing the informed consent.\n2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.\n3. Able and willing to give informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Any burn that at screening is:\n\n   1. infected.\n   2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.\n   3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.\n2. Severe inhalation injury or other significant non-burn trauma.",{"count":368,"type":21},60,[252],"To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to \"time to healing\" (≥95% re-epithelialization) of a partial thickness target thermal burn.",[25],[373],"Burns, Partial Thickness Burns","2026-03-12",{"date":376,"type":32},"2026-03-16",{"date":378,"type":32},"2022-03-11",{"date":380,"type":21},"2026-12-31",{"name":382,"class":39},"Skingenix, Inc.",6,{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":87,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":102},"100552198","phase-2-evolution-of-the-initial-distribution-volume-of-glucose-in-the-severe-burned-adults-100552198","NCT06469970","Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults","INDICIA: Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults","INDICIA","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients hospitalized with burns of at least 30% of body surface area\n\n  * By a thermal mechanism\n  * At the CHR Metz-Thionville burn center\n  * managed within the 8 hours post-burn\n* Patient affiliated to a social security scheme\n* Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign\u002Fexpress consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion.\n\nExclusion Criteria:\n\n* Diabetic patients on insulin\n* Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection\n* Patients with pre-hospital cardiac arrest\n* extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)\n* patient without a central venous line or arterial catheter\n* Patient moribund or immediately subject to therapeutic limitation\n* Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)\n* Pregnant, parturient or breast-feeding women\n* Patient under guardianship, curatorship or safeguard of justice\n* Cognitive impairment or language barrier",{"count":393,"type":21},15,[252],"This is a prospective, observational, monocentric, phase II (exploratory) cohort study aiming to describe the evolutionary profile of the initial volume of glucose distribution (IDVG) during the first four days of management of severely burned patient.",[25,397,398],"Intensive Care","Emergencies","2026-03-10",{"date":374,"type":32},{"date":402,"type":32},"2024-11-28",{"date":404,"type":21},"2027-03-28",{"name":101,"class":76},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":87,"phases":414,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":102},"100561920","phase-2-4-aminopyridine-to-treat-skin-burns-100561920","NCT06596434","4-Aminopyridine to Treat Skin Burns","Inclusion Criteria:\n\n* Injured (burned) adults with a maximum severity of second-degree burns.\n* Burns involving at least 6cm2 of skin area\n* Acute burns within 7 days of injury\n* Cognitive ability to evaluate burn healing, report sensory and motor deficit during examination.\n* Adults aged 18-80\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",{"count":413,"type":21},200,[252],"Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.",[25,417,418],"Second Degree Burn","Wounds and Injuries",[420,421,25,422,423],"4-aminopyridine","4-AP","Second degree burn","Wounds","2026-03-04",{"date":426,"type":32},"2026-03-05",{"date":428,"type":32},"2026-01-01",{"date":430,"type":21},"2028-09",{"name":432,"class":76},"John Elfar",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":87,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":102},"100528536","impact-of-a-telerehabilitation-program-with-technology-enhancement-on-post-burn-recovery-100528536","NCT06162052","Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery","Inclusion Criteria:\n\n* Adults: ≥18 to ≤79 years of age\n* Not participating in another interventional trial\n* Admitted to the Blocker Burn Unit for treatment of initial burn\n* Subject is able and willing to follow the protocol requirements\n* Burn wound \u002F scar \u002F contracture occurring across at least one joint.\n* Has regular access to smart phone, tablet, or computer with internet access.\n\nExclusion Criteria:\n\n* Any medical condition that, in the opinion of the investigator or physician, would place the subject at increased risk for participation.\n* Concurrent participation on another interventional clinical trial\n* History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.\n* Patients without internet access.","79 Years",{"count":294,"type":21},[89],"The purpose of this study is to examine the effect of participating in a tele-rehabilitation program after a burn.",[25],{"date":445,"type":32},"2026-03-06",{"date":447,"type":32},"2024-04-02",{"date":449,"type":21},"2027-12",{"name":451,"class":76},"The University of Texas Medical Branch, Galveston",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":314,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":102},"100612906","lipopolysaccharide-adsorption-efferon-lps-in-patients-with-thermal-burns-100612906","NCT07259668","Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns","An Observational Pilot Study Evaluating the Efficacy and Safety of LPS Adsorption Using the Efferon LPS Device in Patients With Thermal Burns","Inclusion Criteria:\n\n* Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29)\n* Burn disease in the stage of acute toxemia or septicemia\n* Frank Index ≥ 90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion)\n* The patient's condition allows for Efferon LPS therapy for at least 6 hours\n\nExclusion Criteria:\n\n* Isolated thermal inhalation injury\n* Charlson Comorbidity Index \\> 8\n* Dementia\n* End-stage renal failure\n* Acute pulmonary embolism confirmed by CT\n* Acute myocardial infarction within the past 4 weeks\n* Acute cerebrovascular accident\n* Uncontrolled bleeding (acute blood loss within the past 24 hours)\n* Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study",{"count":393,"type":21},"This observational pilot study aims to establish criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury. Participants will be prospectively enrolled into the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with a 24 hours interval between sessions. The procedures may be performed in combination with hemofiltration or hemodiafiltration at the investigator's discretion.",[25],[320,321,322,323],"2026-01-21",{"date":465,"type":32},"2026-01-22",{"date":467,"type":32},"2025-12-08",{"date":469,"type":21},"2028-03-31",{"name":332,"class":39},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":478,"maxAge":314,"enrollmentInfo":479,"targetDuration":4,"studyType":87,"phases":480,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":102},"100614251","the-effect-of-mobile-robot-assisted-gait-training-on-gait-performance-in-chronic-patients-with-impaired-gait-function-after-burn-injury-100614251","NCT07277166","The Effect of Mobile Robot Assisted Gait Training on Gait Performance in Chronic Patients With Impaired Gait Function After Burn Injury","The Effect of Mobile Robot Assisted Gait Training on Gait Performance in Chronic Patients With Impaired Gait Function After Burn Injury : Pilot Study","Inclusion Criteria:\n\n* chronic patients who underwent split-thickness skin grafting or burns of more than 50% of the lower extremities and still had impaired gait dysfunction 6 months later. -aged over 18 years\n* had a Functional Ambulation Category (FAC) score of 3 or higher\n\nExclusion Criteria:\n\n* fourth-degree burns (involving muscles, tendons, and bone injuries)\n* severe communication disorders because of intellectual impairment and psychological problems\n* Patients with body types that prevent them form wearing the robot, such as a height of 4.59 feet (140cm) or 5.91 feet (185cm) or more, or severe obesity with a BMI of 35 or more.\n* Patients with heart and circulatory conditions that may affect gait training.\n* Patients at a high risk of falling during gait training, owing to severe dizziness and having experienced a fall within the preceeding 2 month.","19 Years",{"count":275,"type":21},[89],"This study aims to examine the clinical effectiveness of gait training using wearable robots in patients with impaired gait function after burn injury. The participants were chronic patients who underwent split-thickness skin grafting or burns of more than 50% of the lower extremities and still had impaired gait dysfunction 6 months later. Eligible participants were aged over 18 years and had a Functional Ambulation Category (FAC) score of 3 or higher. Physiotherapy was performed on a one to one basis by qualified physiotherapists for 1 hour per day, 5 days a week Monday through Friday, for 12 weeks. Assessments were carried out before and immediately after the 12-week training period. Physical ability were assessed using the functional ambulatory category(FAC) scale, the 6-Minute Walk Test (6MWT), and the visual analogue scale (VAS). Spatiotemporal gait parameters-including gait speed, cadence, and step length-and sagittal joint kinematic parameters for the hip, knee, and ankle during stance and swing phases were measured during gait analysis. Pulmonary function test such as forced vital capacity (FVC), 1-s forced expiratory volume (FEV1), and carbon monoxide (DLco). The highest maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) value were evaluated.",[25,483,484],"Gait Dysfunction","Robot Training",[486],"BURNS, Gait dysfunction, Wearable robot, Robot training","2025-12-10",{"date":489,"type":32},"2025-12-11",{"date":491,"type":32},"2025-05-13",{"date":493,"type":21},"2026-12-15",{"name":495,"class":76},"Hangang Sacred Heart Hospital",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":87,"phases":503,"briefSummary":504,"conditions":505,"keywords":508,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":512,"leadSponsor":514,"locationsCount":516},"100614153","pilot-feasibility-trial-of-a-peer-support-program-for-trauma-survivors-100614153","NCT07275892","Pilot Feasibility Trial of a Peer Support Program for Trauma Survivors","Inclusion Criteria:\n\n* adult patients (18 years+) who have experienced an unintentional traumatic injury resulting in hospitalization at Sunnybrook and who will be discharged to inpatient rehabilitation at St. John's Rehab after acute care.\n* must be able to communicate in English\n\nExclusion Criteria:\n\n* patients who experienced: a) an intentional self-harm injury (because self-harm suggests a history of mental health issues prior to the trauma requiring specific psychiatric supports)\n* patients who experienced: an injury caused by an intimate partner (because these injuries are typically underpinned by chronic exposure to domestic violence which requires interventions that promote patient safety and interrupt the pattern of violence)\n* patients who experienced: a violently-acquired injury (as this patient population already receives specific clinical and social support through Sunnybrook's BReAking the Cycle of Violence with Empathy (BRAVE) program).\n* patients with substantial cognitive impairment and a history of substance misuse if their HCPs indicate that either condition will impede the their ability to provide informed consent and\u002For participate safely in the trial",{"count":5,"type":21},[89],"Traumatic injuries from events like car crashes, falls, or fires are a leading cause of disability. Survivors often face not only physical challenges but also long-lasting pain, mental health challenges and difficulty returning to work and family life. Although medical care focuses on physical recovery, survivors frequently report that their emotional and social needs are overlooked and unmet.\n\nPeer support-guidance from people who have lived through similar injuries-can reduce distress and improve coping. However, no programs in Canada currently provide peer support to trauma survivors across their recovery journey, from hospital to rehabilitation to community living.\n\nThe investigators worked with trauma survivors, caregivers, and healthcare providers to co-design a Peer Support Program (PSP) that offers support throughout these stages. This pilot study will test whether the program is feasible and acceptable, and explore its early impact on recovery. Results will guide a future larger trial to expand peer support in trauma care.",[116,25,506,507],"Amputation","Mental Health Outcomes",[509,116],"Peer Support",{"date":487,"type":32},{"date":428,"type":21},{"date":513,"type":21},"2027-12-31",{"name":515,"class":76},"Sunnybrook Health Sciences Centre",2,{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":18,"minAge":524,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":87,"phases":528,"briefSummary":529,"conditions":530,"keywords":534,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":546,"locationsCount":102},"100539426","vr-pat-and-fnirs-to-identify-cns-biomarkers-of-pain-100539426","NCT06303687","VR-PAT and fNIRS to Identify CNS Biomarkers of Pain","Imaging Pain in a Virtual World: Neuroimaging Biomarkers for Assessing Brain Mechanisms Mediating Virtual Reality Pain Management in Children","Inclusion Criteria:\n\n1. Being treated for acute burn injury\n2. Age 6-17 years, inclusive\n3. Admitted to NCH burn unit for treatment\n4. Have a dressing that requires daily changes over 3 days\n5. Patient and family caregivers can communicate (read and write) using English\n\nExclusion Criteria:\n\n1. Any wounds that may interfere with study procedures\n2. Vision, hearing, or cognitive\u002Fmotor impairments preventing valid administration of study measures\n3. History of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras\n4. Minors in foster care, prisoners, or currently pregnant\n5. Suspected child abuse\n6. Unable to communicate in English","6 Years","17 Years",{"count":527,"type":21},4,[89],"This study aims to use functional near-infrared spectroscopy (fNIRS) to identify and quantify pain biomarkers during burn dressing changes and pain relief induced by virtual reality (VR).",[531,532,533,25],"Acute Pain","Pediatric ALL","Procedural Pain",[535,536,537,538,539,540],"Virtual Reality","VR","fNIRS","Pain","Biomarker","Neuroimaging","2025-11-19",{"date":543,"type":32},"2025-11-24",{"date":71,"type":21},{"date":210,"type":21},{"name":547,"class":76},"Nationwide Children's Hospital",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":555,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":516},"100612080","lipopolysaccharide-adsorption-efferon-lps-neo-in-children-with-thermal-burns-100612080","NCT07248930","Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns","An Observational Pilot Study Evaluating the Efficacy and Safety of LPS Adsorption Using the Efferon LPS NEO Device in Children With Thermal Burns","Inclusion Criteria:\n\n* Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29)\n* Frank index \\>90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion)\n* Start of hemoadsorption no later than 5 days after admission to the ICU\n* The patient should receive adequate infusion therapy (at least 30 mL\u002Fkg) from the moment of inclusion in the study until the first sorption\n* The patient's condition allows Efferon LPS NEO therapy to be performed for at least 6 hours\n\nExclusion Criteria:\n\n* Presence of end-stage renal disease\n* Acute pulmonary embolism, confirmed by CT scan\n* Uncontrolled bleeding (acute blood loss within the last 24 hours)","1 Year","14 Years",{"count":294,"type":21},"This observational pilot study aims to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS NEO device in pediatric burn injury. Participants will be prospectively assigned to the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with an interval of 24-120 hours between procedures. The sessions may be performed in combination with hemofiltration or hemodiafiltration at the discretion of the investigator.",[25],[320,321,322,323],"2025-11-18",{"date":563,"type":32},"2025-11-25",{"date":565,"type":32},"2025-10-01",{"date":567,"type":21},"2027-03-31",{"name":332,"class":39},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":87,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":516},"100581987","autologous-point-of-care-adipose-therapy-recent-injury-100581987","NCT06857448","Autologous Point-of-Care Adipose Therapy: Recent Injury","Autologous Point-of-Care Adipose Therapy for Reconstruction and Regeneration of Traumatized Skin: Recent Injury","Inclusion Criteria:\n\n* The proposed study will include adult patients 18 years of age or older,\n* male or female,\n* civilian, military, active duty or retired veterans\n* presenting for unilateral or bilateral fasciotomy of the extremity at any level necessary\n* secondary to non-infectious etiology,\n* unilateral or bilateral traumatic full-thickness skin loss of the face, head, neck or extremities necessitating reconstruction, and\u002For\n* full or partial thickness burn injury of the face, neck, or extremity requiring excision and\u002For reconstruction.\n* Additional inclusion criteria includes willingness to be randomized to receive a fat graft.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years of age,\n* active infection,\n* medical co-morbidities or anatomic configuration deemed by the physician to be a concern for safety,\n* unwilling or unable to comply with study procedures,\n* radiation to the site of interest,\n* prisoners and\u002For vulnerable populations.\n* In addition, candidates that are pregnant or plan to become pregnant in the next year, will be excluded.",{"count":577,"type":21},68,[89],"The goal of this study is to explore if an adipose-based therapeutic strategy can treat full-thickness soft-tissue trauma wounds in injured individuals, especially those with severe burns or soft-tissue loss. The main question it aims to answer are:\n\n\\- Can immediate autologous adipose and autologous layered composite grafting be effective for acute functional soft-tissue reconstruction?\n\nResearchers will compare the single-stage autologous layered composite grafting method to traditional methods to see if it improves healing outcomes, minimizes scarring, and reduces infection risk.\n\nParticipants will:\n\n* Receive immediate fat grafting into the wound.\n* Undergo simultaneous split-thickness skin grafting for full soft-tissue reconstruction.",[25,581,582],"Contracture Scar","Surgical Injury",[584,585],"fasciotomy","trauma","2025-11-03",{"date":588,"type":32},"2025-11-05",{"date":590,"type":21},"2025-12",{"date":592,"type":21},"2028-10-30",{"name":594,"class":76},"University of Pittsburgh",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":87,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":613,"locationsCount":516},"100581986","autologous-point-of-care-adipose-therapy-delayed-injuryscar-100581986","NCT06857435","Autologous Point-of-Care Adipose Therapy: Delayed Injury\u002FScar","Autologous Point-of-Care Adipose Therapy for Reconstruction and Regeneration of Traumatized Skin: Delayed Injury\u002FScar","Inclusion Criteria:\n\n* The proposed study will include adult patients 18 years of age or older,\n* male or female,\n* civilian, military, active duty or retired veterans\n* presenting for scar contracture release and reconstruction at any level.\n* Additional inclusion criteria includes willingness to be randomized to receive a fat graft.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years of age,\n* active infection,\n* medical co-morbidities or anatomic configuration deemed by the physician to be a concern for safety,\n* unwilling or unable to comply with study procedures,\n* radiation to the site of interest,\n* prisoners and\u002For vulnerable populations.\n* In addition, candidates that are pregnant or plan to become pregnant in the next year, will be excluded.",{"count":603,"type":21},40,[89],"The goal of this study is to explore if an adipose-based therapeutic strategy can treat contracted scars secondary to soft-tissue burn wounds in injured individuals, especially those with severe burns or soft-tissue loss. The main question it aims to answer are:\n\n\\- Can autologous layered composite grafting demonstrate non-inferiority compared to full-thickness skin grafting for delayed reconstruction of post-burn or trauma scar contracture?\n\nResearchers will compare the single-stage autologous layered composite grafting method to traditional methods to see if it improves healing outcomes, minimizes scarring, and reduces infection risk.\n\nParticipants will:\n\n* Receive fat grafting at time of scar revision.\n* Undergo simultaneous split-thickness skin grafting for full soft-tissue reconstruction.",[25,581,582],[608,609],"burns","scar contracture",{"date":588,"type":32},{"date":590,"type":21},{"date":592,"type":21},{"name":594,"class":76},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":87,"phases":623,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":102},"100545271","phase-4-burn-study--tranexamic-acid-versus-thrombin-in-split-thickness-skin-graft-100545271","NCT06379724","Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft","The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management","Inclusion Criteria:\n\n* English or Spanish speaking\n* Flame or scald burn injury\n* \\\u003C=10% total body surface area (TBSA) partial thickness\n* \\\u003C= 5% total body surface area (TBSA) deep partial or full thickness\n* Skin graft harvested at 1\u002F12 inch depth, meshed 1:1 or pie crusted if the area is a small functional area\n\nExclusion Criteria:\n\n* \\>10% total body surface area (TBSA) partial thickness burn\n* \\>5% total body surface area (TBSA )surgical area of burn injury (deep partial or full thickness injury)\n* Traumatic or chemical burn mechanism\n* Patients on immunosuppression\n* Uncontrolled diabetes\n* Known diagnosis of peripheral vascular disease or diagnosis at time of injury\n* Pregnant women\n* Patients with acquired defective color vision\n* Patients with subarachnoid hemorrhage\n* Patients with active intravascular clotting or known hypersensitivity reactions to tranexamic acid\n* Inability to give informed consent",{"count":622,"type":21},62,[624],"PHASE4","Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.",[25,627],"Skin Graft Complications","2025-10-15",{"date":630,"type":32},"2025-10-20",{"date":632,"type":32},"2024-07-11",{"date":210,"type":21},{"name":635,"class":76},"University of Kansas Medical Center"]